share_log

B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $13

Benzinga ·  Sep 8, 2023 11:26

B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $12 to $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment